This proposed RDL initiative yields promising benefits to pharmacy students and schools. Student-related benefits include encouraging cultivation of research-specific skills, promoting scientific productivity, offering a sense of intellectual fulfillment, and deepening interest in pursuing pharmacist-scientist and academic pharmacy careers. Conversely, pharmacy school-related benefits include highlighting the same significance for research and academic excellence in curricula, displaying the school's research-intensive eminence, increasing the school's pool of scientific output, and supporting budding of accomplished pharmacist-investigator graduates.
Exploring the perceptions of pharmacy students and deans toward the implementation of RDL proposal is warranted. The RDL may be used by admission committees to rank pharmacy students when they apply to research-based scholarships, travel grants, or clinical residency training.
In conclusion, this is the first letter to call for a new implementation of the RDL as an initiative to extrinsically encourage research productivity by pharmacy students. Finally, pharmacy schools should continuously attempt to extrinsically boost their students to undertake meaningful research activities that culminate in fruitful outcomes. Dear Editor, Nowadays, it is not enough for PharmD students to be only clinically competent, but also they need to act research oriented and proficient. [1] According to this philosophy, there is a growing proclivity toward integrating curricular and extracurricular research training into the pharmacy school syllabi worldwide. [2] In general, the participation of students in research is wheeled by intrinsic and extrinsic motivations.
Financial support and sponsorship
[3] The intrinsic motivations are internally self-driven by students, for example, improving their resume. Conversely, extrinsic motivations are externally stimulated by schools through financial and nonfinancial awards. Although the former motivations are essential, the latter ones should never be ignored.
Worldwide in pharmacy schools, the so-called "Academic Dean's List" is an extrinsic award which recognizes students who attain academic distinction on a semester basis -i.e., completing a minimum of 12 letter-graded credit hours and achieving a grade point average of ≥3.75 (cutoffs vary according to individual schools' policies).
[4] It is time to appreciate students' research and their academic distinction as equally important. To that end, pharmacy schools are called to establish the "Research Dean's List (RDL)" which is a novel proposal to encourage academic research and scholarly publishing by PharmD students.
The RDL will be an extrinsically ambitioned award which recognizes students who attain research excellence on a yearly basis. While individual pharmacy schools in each country can define the eligibility requirements, it is more preferred to be done through a national consensus meeting. For instance, in Saudi Arabia, this can be achieved through formulating a designated task force headed by the Saudi Pharmaceutical Society and co-headed by deans of the colleges of pharmacy in the kingdom. Fundamentally, these eligibility requirements should be based on graded objective parameters (e.g., peer-reviewed publications, abstract presentations, earning international or national research prizes, and achieving outstanding scores in research-related modules). Forms of award for inclusion in the RDL may include a special appreciation during the Dean's List awarding ceremony, a commendation letter, and possibly an array of financial incentives (e.g., partial tuition fee waivers). Dear Editor, Piriformis syndrome is a neuromuscular condition caused by irritation or compression of the sciatic nerve in the sub-pyramidal canal.
[1] There are well-established treatments for this condition, including physical modalities and interventions such as corticosteroid or botulinum toxin injections. The use of mannitol infusion to treat piriformis syndrome has not been extensively described. We read with great interest a recent publication by Huang et al. with regard to the combined use of 20% mannitol infusion and oral Vitamins B as a potential treatment modality for this condition.
[2] A few comments can be made from this publication.
First, clinicians need to understand the mode of action of mannitol and interpret studies pertaining to its use carefully. Mannitol, chemically 1,2,3,4,5,6-hexanehexol (C6 H8 [OH] 6) has been widely used in raised intracranial pressure, rhabdomyolysis, and renal protection in cardiovascular conditions due to its osmotic properties. [3] In theory, as a neural prolotherapy agent, mannitol could help in neuromuscular condition by extinguishing pain and reducing pain as in the case of piriformis syndrome. The postulation that mannitol binds to transient receptor potential cation channel subfamily V member 1 receptors, inhibiting the release of inflammatory chemicals from neurons and restoring neural function remains to be validated by future research.
[4] Even though Huang et al. reported a significant reduction in swelling of the sciatic nerve, pain, and function after the combined treatment, there is lack of control groups in the study design of 22 patients who received 5 days of mannitol and 6 weeks of oral Vitamins B.
[1] It remains unclear for the extent of contribution by mannitol per se in clinical improvement. We support the use of mannitol as a treatment modality but suggest future randomized control trials to answer this question.
Second, while mannitol seems promising as a treatment modality, one needs to be mindful of its side effects and when to consider this modality in piriformis syndrome. An in-depth discussion of the potential side effects of mannitol is beyond the scope of this letter; however, clinicians and researchers should be aware of potential side effects such as hypernatremia, heart failure, and allergic reactions.
[3] In cases, where patients fail to respond to conservative treatment, the clinician should discuss the risk-benefits of administrating mannitol. It might be possible to advocate specific guidelines for the use of mannitol in pyriformis syndrome in terms of dosing and duration.
Finally, while it appears reasonable to provide oral Vitamins B for pyriformis syndrome patients who are symptomatic with functional limitation, the treatment regimen in pain relief remains unclear. Current evidence leans toward higher doses and short-term improvement in pain and paresthesia. Vitamins B are common oral medications to treat peripheral neuropathy and neuropathic pain. Specifically, methylcobalamin (Mecbl), one of the analogs of Vitamin B12, has been postulated to have some analgesic property of improving neuropathic pain by enhancing the nerve conduction velocities.
[5] Conditions being treated previously include back pain and various types of neuralgia such as trigeminal neuralgia. In piriformis syndrome, there is, at present, lack of conclusive randomized controlled trial using Mecbl to validate the benefits of pain relief. Oral Vitamins B are safe with few side effects and generally well-tolerated. Therefore, clinicians should be open to the
